Access ESMO scientific and educational resources on this topic
Recent medwireNews and resources from conferences are for ESMO Members only.
Neuroendocrine Cancer
Latest ESMO videos
Featured medwireNews
Neuroendocrine Tumour Treatments Reviewed
Gastroenteropancreatic NETs Show Late Recurrence Patterns
E-Learning
ESMO E-Learning: Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumours
ESMO E-Learning: Current and Future Perspectives of Theranostics in the Field of NETs
ESMO E-Learning: Overview on Management of Lung Neuroendocrine Tumours (Typical and Atypical Carcinoids)
ESMO E-Learning: Overview of the Diagnosis and Treatment of GI NETs
Meeting resources
NETs and endocrine tumours
Presenter: Juan Valle
Session: Congress Highlights 2
Resources:
Slides
Webcast
1645O - Durvalumab (D) plus tremelimumab (T) for the treatment of patients with progressive, refractory advanced thyroid carcinoma: The DUTHY (GETNE-T1812) trial
Presenter: Jaume Capdevila Castillon
Session: Proffered Paper session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
887O - First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with <sup>177</sup>Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial
Presenter: Eric Baudin
Session: Proffered Paper session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
LBA45 - Randomized open label phase III study comparing the efficacy and safety of everolimus followed by chemotherapy (CT) with streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs: The SEQTOR study (GETNE 1206)
Presenter: Ramon Salazar
Session: Proffered Paper session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
Small cell lung cancer: How molecular insights have shed light on aggressive clinical behaviour
Presenter: Charles Rudin
Session: Hard-to-treat cancers: What makes them special?
Resources:
Slides
Webcast